Literature DB >> 8605364

Neutrophil deactivation by influenza A viruses: mechanisms of protection after viral opsonization with collectins and hemagglutination-inhibiting antibodies.

K L Hartshorn1, K B Reid, M R White, J C Jensenius, S M Morris, A I Tauber, E Crouch.   

Abstract

Bacterial superinfections are a major cause of morbidity and mortality during influenza A virus (IAV) epidemics. Depression of phagocyte functions resulting from attachment of the IAV hemagglutinin (HA) to cell surface sialo-glycoproteins is a likely contributory cause of these infections. We have proposed that the group of collagenous lectins (termed collectins) present in blood and pulmonary surfactant play a role in initial host defense against IAV. We used here several recombinant human surfactant protein D (RhSP-D) preparations to determine the mechanism through which opsonization of IAV with collectins protects neutrophils against the deactivating effects of IAV on cellular respiratory burst responses in vitro. RhSP-D was markedly more potent than antibodies that inhibited viral hemagglutination activity (anti-HA antibodies) at protecting neutrophils in this assay. Unlike the anti-HA antibodies, RhSP-D was protective at concentrations that minimally inhibited viral hemagglutination activity. Two related features of SP-D--the degree of multimerization and the ability to cause aggregation of IAV particles--were critical determinants of the ability of SP-D to protect neutrophils against deactivation. Similarly SP-D-induced viral aggregate formation resulted in enhanced IAV binding to neutrophils and potentiated the ability of the virus itself to trigger neutrophil respiratory burst responses. In contrast to the case of IAV-antibody complexes, SP-D-IAV complexes attached to and activated neutrophils through a neuraminidase-sensitive mechanism (ie, similar to unopsonized IAV). These results indicate that collectin-mediated viral aggregation per se may be an important host defense mechanism not only by virtue of reducing the number of infectious viral particles, but also by promoting phagocyte responsiveness.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605364

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice.

Authors:  Michelle D Tate; Danielle L Pickett; Nico van Rooijen; Andrew G Brooks; Patrick C Reading
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice.

Authors:  P C Reading; L S Morey; E C Crouch; E M Anders
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Salivary Blockade Protects the Lower Respiratory Tract of Mice from Lethal Influenza Virus Infection.

Authors:  Karen Ivinson; Georgia Deliyannis; Leanne McNabb; Lara Grollo; Brad Gilbertson; David Jackson; Lorena E Brown
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

4.  Introduction of N-linked glycans in the lectin domain of surfactant protein D: impact on interactions with influenza A viruses.

Authors:  Martin van Eijk; Laurie Bruinsma; Kevan L Hartshorn; Mitchell R White; Michael J Rynkiewicz; Barbara A Seaton; Wieger Hemrika; Roland A Romijn; Bas W van Balkom; Henk P Haagsman
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

5.  Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Authors:  Monica Vaccari; Shari N Gordon; Slim Fourati; Luca Schifanella; Namal P M Liyanage; Mark Cameron; Brandon F Keele; Xiaoying Shen; Georgia D Tomaras; Erik Billings; Mangala Rao; Amy W Chung; Karen G Dowell; Chris Bailey-Kellogg; Eric P Brown; Margaret E Ackerman; Diego A Vargas-Inchaustegui; Stephen Whitney; Melvin N Doster; Nicolo Binello; Poonam Pegu; David C Montefiori; Kathryn Foulds; David S Quinn; Mitzi Donaldson; Frank Liang; Karin Loré; Mario Roederer; Richard A Koup; Adrian McDermott; Zhong-Min Ma; Christopher J Miller; Tran B Phan; Donald N Forthal; Matthew Blackburn; Francesca Caccuri; Massimiliano Bissa; Guido Ferrari; Vaniambadi Kalyanaraman; Maria G Ferrari; DeVon Thompson; Marjorie Robert-Guroff; Silvia Ratto-Kim; Jerome H Kim; Nelson L Michael; Sanjay Phogat; Susan W Barnett; Jim Tartaglia; David Venzon; Donald M Stablein; Galit Alter; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  Nat Med       Date:  2016-05-30       Impact factor: 53.440

6.  Enhancement of antiviral activity of collectin trimers through cross-linking and mutagenesis of the carbohydrate recognition domain.

Authors:  Mitchell R White; Patrick Boland; Tesfaldet Tecle; Donald Gantz; Grith Sorenson; Ida Tornoe; Uffe Holmskov; Barbara McDonald; Erika C Crouch; Kevan L Hartshorn
Journal:  J Innate Immun       Date:  2009-12-24       Impact factor: 7.349

7.  Structure of a truncated human surfactant protein D is less effective in agglutinating bacteria than the native structure and fails to inhibit haemagglutination by influenza A virus.

Authors:  S Eda; Y Suzuki; T Kawai; K Ohtani; T Kase; Y Fujinaga; T Sakamoto; T Kurimura; N Wakamiya
Journal:  Biochem J       Date:  1997-04-15       Impact factor: 3.857

8.  Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.

Authors:  J K van de Wetering; F E J Coenjaerts; A B Vaandrager; L M G van Golde; J J Batenburg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Viral aggregating and opsonizing activity in collectin trimers.

Authors:  Kevan L Hartshorn; Mitchell R White; Tesfaldet Tecle; Grith Sorensen; Uffe Holmskov; Erika C Crouch
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-10-16       Impact factor: 5.464

10.  Pulmonary collectins modulate strain-specific influenza a virus infection and host responses.

Authors:  Samuel Hawgood; Cynthia Brown; Jess Edmondson; Amber Stumbaugh; Lennell Allen; Jon Goerke; Howard Clark; Francis Poulain
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.